ADPT vs IDYA: fair value comparison
Adaptive Biotechnologies Corporation and IDEAYA Biosciences, Inc. · Updated 2026-10-19
ADPT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. IDYA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ADPT currently ranks higher by quality score.
| ADPT | IDYA | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $24.02 | $32.85 |
| 12-month range | $12.41–$29.84 | $27.60–$42.48 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #141 of 301 Healthcare | #143 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | High | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: ADPT fair value analysis · IDYA fair value analysis